Seven Suggestions for Successful SGLT2i Use in Glomerular Disease

A Standalone CKD Therapy?

Emily P. McQuarrie; Keith A. Gillis; Patrick B. Mark


Curr Opin Nephrol Hypertens. 2022;31(3):272-277. 

In This Article


SGLT2i have proven benefits for patients with CKD and proteinuria, the like of which has not been seen before. It is the duty of clinicians to target the initiation of these medicines promptly and appropriately as above, in order that patients can accrue the benefits, which have been sorely lacking up until this point. It is expected that the remit for these drugs will widen in the near future and as clinicians become familiar with their usage, they should become cornerstones of standard nephrology care.